PATENT CLAIM ANALYSIS

Application Number: 15924940
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "451000"]

Abstract:
The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

Claim (Index 13):
The oral dosage formulation of  claim 12 , wherein the unit does is 3 mg.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 90.0
- Lexical Diversity: 1.18182
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15467631', '13421769', '14845644', '14301812', '14001638']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7813462161672491
- 35 USC 102 Novelty (BERT): 0.595975503868301
- Combined Prediction Score: 0.7628091449373543
- Mean Citation Score: 481.11938
- Max Citation Score: 510.3054
- Similarity Product: 316.6014756071091

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test